surmount-1 tirzepatide weight loss non-diabetic (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants SURMOUNT‐1 study design. This is

The standard dosing protocol calls for one injection per week, taken on the same day each week for consistent results

Incretin receptor agonists, including tirzepatide, may potentially increase the risk of thyroid C-cell tumors based on findings in animal studies

Scientific Evidence & Clinical Studies The popularity of GLP-1 receptor agonists has expanded rapidly

The injectable medication is a new version of Eli Lillys Mounjaro, which is approved by the FDA to control blood sugar in people with Type 2 diabetes

FULL FAT DAIRY NO SUGAR* Rebel gives you the goodness of dairy without any of the downsides

Reaching steady state typically takes 4-5 weeks of consistent dosing